Published in Medical Letter on the CDC and FDA, August 22nd, 2004
According to published research from the United States, "Since myelin basic protein (MBP) 111-129 is an immunodominant epitope in humans carrying HLA-DRB1*0401, we investigated the encephalitogenic potential of HLA-DRB1*0401-restricted MBP111-129-specific T cells using HLA-DRB1*0401/DRA*0101 transgenic (Tg) mice. Although we could not detect the primary recall response to MBP111-129 peptide after immunization of HLA-DRB1*0401/DRA*0101 Tg mice with human MBP, Vbeta10+ and Vbeta2+ HLA-DRB1*0401-restricted MBP111-129-specific T cells proliferated after restimulation of the lymph node cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA